Observational Study of Durvalumab in Patients With Non-small-cell Lung Cancer in the United Kingdom

CompletedOBSERVATIONAL
Enrollment

115

Participants

Timeline

Start Date

June 24, 2021

Primary Completion Date

September 28, 2022

Study Completion Date

September 28, 2022

Conditions
Non-Small Cell Lung Cancer NSCLC
Interventions
DRUG

Durvalumab

Durvalumab

Trial Locations (10)

CT1 3NG

East Kent Hospital, Canterbury

CF14 2TL

Velindre Hospital, Cardiff

HG2 7SX

Harrogate and district NHS foundation Trust, Harrogate

LS9 7TF

Leeds Teaching Hospitals NHS Trust, Leeds

SE1 9RT

Guy's Hospital, London

SW3 6JJ

The Royal Marsden NHS Foundation Trust, London

M20 4BX

The Christie NHS Foundation, Manchester

PO6 3LY

Queen Alexandra Hospital, Portsmouth

TA1 5DA

Musgrove Park Hospital, Taunton

TR1 3LJ

Royal Cornwall Hospitals NHS Trust, Truro

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY